

RESEARCH ARTICLE

Open Access

# Influence of *IL17A* polymorphisms on the aberrant methylation of *DAPK* and *CDH1* in non-cancerous gastric mucosa

Tomiyasu Arisawa<sup>1\*</sup>, Tomomitsu Tahara<sup>2</sup>, Mikihiro Tsutsumi<sup>1</sup> and Tomoyuki Shibata<sup>2</sup>

## Abstract

**Background:** CpG island aberrant methylation is shown to be an important mechanism in gene silencing. The important role of IL-17 in inflammatory response to *H. pylori* colonization has been indicated. We investigated the influence of *IL17A* polymorphisms, -197 G > A (rs2275913) and \*1249 C > T (rs3748067), on the methylation of *DAPK* and *CDH1*.

**Methods:** Gastric mucosal samples were obtained from 401 subjects without malignancies. Methylation status of gene was determined by MSP. The genotyping of *IL17A* was performed by PCR-SSCP.

**Results:** Methylations of *DAPK* and *CDH1* were seen in 196 and 149 of all 401 subjects, respectively. Overall, \*1249 T carrier was associated with a decreased risk for *DAPK* methylation, whereas -197 G > A was not. In the subjects older than 60 years old, \*1249 T carrier was more strongly associated with gene methylation and -197 A carrier tended to be associated with an increased risk for *CDH1* methylation. When evaluating by inflammation promoting haplotype (-197 mutant carrier with \*1249 homozygote), this haplotype had a more strongly increased risk for both *DAPK* and *CDH1* methylations in comparatively older subjects. Both atrophy and metaplasia scores were significantly increased with age in -197 A carrier or \*1249 CC homozygote, whereas were not in -197 GG homozygote or \*1249 T carrier. PG I/II ratio was more significantly decreased in -197 A carrier than in GG homozygote under influence of *H. pylori* infection.

**Conclusions:** In -197 A allele carrier with \*1249 CC homozygote, the methylations of both *DAPK* and *CDH1* may be increased gradually, but more rapidly than the other genotypes, with age and altered gastric mucosal structure induced by *H. pylori* infection.

**Keywords:** *IL17A*, Aberrant DNA methylation, *DAPK*, *CDH1*

## Background

Interleukin-17 (IL-17) is a relatively newly described cytokine that bridges the adaptive and innate immune systems. IL-17A is a cytokine responsible for the pathogenic activity of the Th17 cells [1], a distinct lineage of CD4+ effector cells [2]. IL-17A induces multiple proinflammatory mediators, including chemokines, cytokines, and metalloproteinases, from epithelial and fibroblast cells [3]. An enhanced expression of IL-17 has been also documented and implicated in the pathogenesis of

immune-mediated diseases, such as rheumatoid arthritis, multiple sclerosis, and psoriasis [4]. In addition, IL-17 has the ability to stimulate IL-8 production in both epithelial cells and macrophages [5,6], raising the possibility that this cytokine may play an important role in the recruitment of inflammatory cells during bacterial infections. At first, Lussa et al. reported that bio-active IL-17A production was increased during *Helicobacter pylori* (*H. pylori*) infection, suggesting the possibility that this cytokine may play an important role in the *H. pylori*-induced inflammatory response [7]. Thereafter, several studies reported that IL-17 stimulates IL-8 release by gastric epithelial cells and facilitates the chemotaxis of neutrophils through an IL-8-dependent mechanism,

\* Correspondence: tarisawa@kanazawaed.ac.jp

<sup>1</sup>Department of Gastroenterology, Kanazawa Medical University, 1-1, Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan

Full list of author information is available at the end of the article

and contributes to the enhancement of IL-8 levels in *H. pylori*-colonized gastric mucosa [8-10].

On the other hand, gastric cancer is one of the most common cancers worldwide [11,12], but the etiology of this tumor remains unclear. *H. pylori* infection is now accepted as a crucial event in the development of peptic ulcer disease and atrophic gastritis, and it is implicated in the development of gastric carcinoma, especially not located in cardia [13-15]. Several cancers, including gastric tumors, show methylations of multiple genes including E-cadherin gene (*CDHI*), death-associated protein kinase gene (*DAPK*) and *CDKN2A* [16,17]. Some genes are also methylated in non-neoplastic tissues with aging, and this alteration is known as age-related methylation [18,19]. In addition, it has also shown that gene methylation may be present in chronic inflammation of various tissues [20,21]. In gastric mucosa, it was indicated that methylation of CpG island was induced by *H. pylori* infection in non-cancerous mucosa [22,23] and considered as the precancerous conditions in gastric carcinogenesis [24]. Among several genes, *DAPK* and *CDHI*, as well as *CDKN2A*, are frequently methylated in non-neoplastic gastric mucosa in relation to age, *H. pylori* infection, histological degree of gastritis, and gastric carcinogenesis [22,25,26].

Recently, we have reported that the IL-17A gene (*IL17A*) polymorphism (rs2275913 G > A) and IL-17 F gene (*IL17F*) polymorphism (rs763780 T > C) are closely associated with the susceptibility to gastric carcinogenesis [27], as well as ulcerative colitis [28]. Thereafter, several studies revealed the association between *IL17A* rs2275913 G > A and rheumatoid arthritis, gastric carcinogenesis and asthma [29-31]. The rs2275913 (G/A), located at a position -197 from the starting codon of *IL17A*, may regulate the expression of mRNA. In addition, there is a polymorphism rs3748067 (\*1249 C > T) in *IL17A* 3'-UTR, targeted by some microRNAs. We hypothesize that these *IL17A* gene polymorphisms may influence the development of aberrant DNA methylation of gastric mucosa.

In the present study, we investigated the association between polymorphisms of *IL17A*, rs2275913 (-197 G > A) and rs3748067 (\*1249 C > T), and the aberrant DNA methylation of *DAPK* and *CDHI* in non-cancerous gastric epithelium.

## Methods

### Clinical samples

The studied population comprised 401 subjects without gastric malignancies recruiting the Endoscopy Center of Fujita Health University Hospital or Kanazawa Medical University Hospital. In HapMap-JPT, the frequency of *IL17A* -197 A allele frequency was 45.3%. We assume that a 20% decrease in the prevalence of an allelic frequency would be clinical relevance (unmethylated group: 40% vs.

methylated group: 50%). Assuming an alpha value = 0.05 and a power = 0.80, at least 200 unmethylated subjects and 200 methylated subjects would be sufficient to identify a clinical relevant difference. Accordingly, 400 subjects would be clinical relevance for the study. All subjects underwent upper endoscopy with one or two biopsy specimens from non-cancerous mucosa in antrum. Parts of each specimen was fixed in 10% buffered formalin and embedded in paraffin, while the other part was immediately frozen and stored at -80°C. Later, Genomic DNA was isolated from frozen specimens using proteinase K. A specimen from the subjects who consented to only one biopsy was not used for the histological evaluation.

The subjects without methylation of both *DAPK* and *CDHI* were classified into non CIHM (CpG island high methylated) group, whereas the others except non CIHM were classified into CIHM group. Furthermore, the subjects were divided into 2 groups by genotype as follows:

HR (high risk) group: *IL17A* -197 A carrier with \*1249 CC genotype

LR (low risk) group: the subjects except HR group

The Ethics Committees of the Fujita Health University and Kanazawa Medical University approved the protocol, and prior, written informed consent was obtained from all participating subjects.

### Bisulfate modification and Methylation-Specific PCR (MSP)

To examine DNA methylation, genomic DNA was treated with sodium bisulfite using BisFast DNA Modification Kit for Methylated DNA Detection (TOYOBO, Co., Ltd., Osaka, Japan). MSP for *DAPK* and *CDHI* were carried out using the methods reported by Katzenellenbogen et al. [32] and Herman et al. [33], respectively. In brief, MSP reactions were carried out with primer pairs described below, using EX Taq HS (Takara Bio, Inc., Shiga, Japan).

Primer pairs:

*DAPK*: methylated forward; 5'-ggatagtcggatcgagttacgctc-3', reverse; 5'-ccctcccaaacgccga-3'

*DAPK*: unmethylated forward; 5'-ggaggatagttggattgagttatgtt-3', reverse; 5'-caaatccctcccaaacaccaa-3'

*CDHI*: methylated forward; 5'-ttaggttagagggttatcgctg-3', reverse; 5'-taactaaaattcacctaccgac-3'

*CDHI*: unmethylated forward; 5'-taatttaggttagagggttatgtt-3', reverse; 5'-cacaaccaatcaacaacaca-3'

An annealing temperature and times were determined using DNA from peripheral blood of a young individual without *H. pylori* infection and DNA methylated with SssI methylase (NEW ENGLAND BioLabs Inc., Beverly, MA). The MSP was carried out in a volume of 20 µL containing 0.1 µg of bisulfite-modified DNA. The bands of MSP were detected by electrophoresis in 3.0% agarose gels stained with ethidium bromide. Hyper-methylation was defined as the presence of a positive methylation band showing signals approximately equal to or greater than that of the size marker (10 ng/ µL: 100 bp DNA Ladder, Takara Bio, Inc., Shiga, Japan) regardless of the presence of unmethylated bands.

### Genotyping of polymorphisms

The DNA isolated from biopsy specimens or peripheral blood was used. Polymorphism was genotyped by PCR-SSCP method as reported previously [27,28]. To detect *IL-17A* \*1249 C > T using the primer pairs (1249F: 5'-c ccctcagatcaacagaccaaca-3' and 1249R: 5'-gcgaaatggtac gatgtaaacttg-3'), PCR was carried out in a volume of 20 µL containing 0.1 µg of genomic DNA. The DNA was denatured at 95°C for 3 minutes, followed by 35 cycles at 95°C for 30 seconds, 52°C for 40 seconds, and 72°C for 45 seconds, with final extension at 72°C for 5 minutes. Thereafter, 2 µL of the PCR product was denatured with 10 µL of formamide (Sigma-Aldrich Co., St. Louis, USA) at 90°C for 5 minutes. SSCP was carried out at 18°C using a GenePhor DNA separation system with GeneGel Excel 12.5/24 (Amersham Biosciences Corp., USA), after which the denatured single strand DNA bands were detected using a DNA Silver Staining Kit (Amersham Biosciences Corp.).

To detect *IL-17A* -197 G > A, using the primer pairs (*IL17AF*: 5'-aacaagtaagaatgaaaagaggacatggt-3' and *IL17AR*: 5'-cccccaatgaggtcatagaagaatc-3'), PCR was carried out in a volume of 20 µL containing 0.1 µg of genomic DNA. The DNA was denatured at 96°C for 90 s, followed by 35 cycles at 96°C for 15 s, 58°C for 30 s, and 72°C for 45 s, with final extension at 72°C for 3 min. Thereafter, SSCP was carried out at 6°C as a same manner described above.

### Histological evaluation

In 286 of 401 subjects, the severity of chronic gastritis was classified according to the updated Sydney system [34] by a pathologist who had no access to any clinical information.

### Serological evaluation

The pepsinogen (PG) I/II ratio was calculated based on the data of the serum PG I and PG II levels measured by radioimmunoassay in 74 of 401 subjects. A PG I/II ratio that showed a decrease in proportion to the severity of

gastric mucosal atrophy was used as a marker of atrophic gastritis [35,36].

### Statistical analysis

The data were expressed as mean ± SD. Mean ages between 2 groups was compared by Student's *t*-test. The ratio of *H. pylori* infection status and male/female was compared by Fisher's exact test. Allele and genotype frequencies were calculated by direct counting. The allele counts were also compared by a Fisher's exact test. The strength of association between allele frequencies and the disease was assessed by calculating the odds ratio (OR) and 95% confidence intervals (CI) by logistic regression analysis. Adjusted ORs were calculated after adjustment for age, gender and *H. pylori* infection status. Each updated Sydney system score and PG I/II ratio between 2 groups were compared by Mann Whitney U-test. The relationship between age and updated Sydney system score was assessed by ANCOVA. When setting  $\alpha = 0.05$ , the  $\beta$  value was calculated by Post-hoc analysis. For all analyses, the level of significance was set at  $p < 0.05$ .

## Results

### Subjects and genotype

The characteristics of subjects were summarized in Table 1. *H. pylori* positive ratio was significantly higher in CIHM group than in non CIHM group. The

**Table 1 Characteristics of the subjects and frequency of genotypes**

	Total	non CIHM	CIHM	p value*
number of subjects	401	153	248	
mean age ± SD	60.0 ± 13.8	60.2 ± 13.7	59.9 ± 13.9	NS
male : female	230 : 171	87 : 66	143 : 105	NS
<i>H. pylori</i> positive rate	241/401	71/153	170/248	<0.0001
-197 G > A				
GG	155	65	90	
GA	204	74	130	
AA	41	14	27	
(unknown)	1	0	1	
A allele frequency	35.8%	33.3%	37.2%	NS
*1249 C > T				
CC	340	124	216	0.058 <sup>a</sup>
CT	42	20	22	
TT	16	9	7	
(unknown)	3	0	3	
T allele frequency	9.3%	12.4%	7.3%	0.023

non CIHM: neither *DAPK* nor *CDH1* were methylated.

CIHM: both or either *DAPK* or *CDH1* was methylated.

\*: unmethylated vs. methylated.

a: frequency of \*1249 CC genotype.

**Table 2 Distributions of IL17A genotypes and gene methylations**

	<i>DAPK</i>			<i>CDH1</i>		
	Unmethylated	methylated	p value*	unmethylated	methylated	p value*
number of subjects	205	196		252	149	
mean age ± SD	59.3 ± 13.6	60.8 ± 13.9	NS	60.1 ± 14.1	59.9 ± 13.2	NS
male : female	118 : 87	112 : 84	NS	145 : 107	85 : 64	NS
<i>H. pylori</i> positive rate	104/205	137/196	<0.0001	131/252	110/149	<0.0001
-197 G > A						
GG	86	69	98	57		
GA	99	105	128	76		
AA	19	22	26	15		
(unknown)	1	0	0	1		
A allele frequency	33.6%	38.0%	NS	35.7%	35.8%	NS
*1249 C > T						
CC	167	173	0.023 <sup>a</sup>	210	130	
CT	28	14		28	14	
TT	10	6	11	5		
(unknown)	0	3		3	0	
T allele frequency	7%	6.7%	0.020	10.0%	8.2% NS	

\*: unmethylated vs. methylated.  
 a: frequency of \*1249 CC genotype.

distribution of -197 G > A genotype in non CIHM group was 65GG, 74GA and 14AA. It was in the Hardy-Weinberg equilibrium ( $p = 0.36$ ). That of \*1249 C > T was 124CC, 20CT and 9TT, which was not in the Hardy-Weinberg equilibrium. The distribution of -197 G > A genotype was not different among two groups. However, the frequencies of \*1249 minor allele was significantly lower in CIHM group than non CIHM group ( $p = 0.023$ ,  $1-\beta$ power = 0.636).

#### Distributions of IL17A genotypes and gene methylations

The *H. pylori* positive ratio was significantly higher in methylated group than in unmethylated group of *DAPK* or *CDH1* (Table 2). The distribution of -197 G > A genotype was not different among two groups of both genes,

whereas the frequency of \*1249 CC homozygote was significantly higher in methylated group than in unmethylated group of *DAPK* ( $p = 0.023$ ). In addition, the minor allele frequency was significantly lower in methylated group than in unmethylated group of *DAPK* ( $p = 0.020$ ,  $1-\beta$ power = 0.641). However, the distribution of \*1249 C > T genotype was not different among two groups of *CDH1*.

#### Risk of IL17A polymorphisms for the gene methylation

The -197 G > A was not associated with CIHM and was not associated with each *DAPK* and *CDH1* methylations (Table 3). On the other hand, \*1249 C > T tended to be associated with CIHM (OR, 0.611; 95%CI, 0.343-1.09;  $p = 0.096$ , Table 4). Meanwhile, \*1249 mutant carrier had

**Table 3 Association between IL17A -197 G > A polymorphism and gene methylation**

CIHM ( <i>DAPK</i> or <i>CDH1</i> )	GG	GA	AA	unknown	A carrier vs. GG; OR (95%CI)	p value
unmethylated (153)	65	74	14	0	reference	-
methylated (248)	90	130	27	1	1.33 (0.870-2.04)	0.19
<i>DAPK</i>						
unmethylated (205)	86	99	19	1	reference	-
methylated (196)	69	105	22	0	1.37 (0.907-2.08)	0.13
<i>CDH1</i>						
unmethylated (252)	98	128	26	0	reference	-
methylated (149)	57	76	15	1	1.04 (0.676-1.60)	0.86

by logistic regression analysis after adjustment for age, gender and *H. pylori* infection status.  
 ( ): number of subjects.

**Table 4 Association between IL17A \*1249 C > T polymorphism and gene methylation**

CIHM ( <i>DAPK</i> or <i>CDH1</i> )	CC	CT	TT	unknown	T carrier vs. CC; OR (95%CI)	p value
unmethylated (153)	124	20	9	0	reference	-
methylated (248)	216	22	7	3	0.611 (0.343-1.09)	0.096
<i>DAPK</i>						
unmethylated (205)	167	28	10	0	reference	-
methylated (196)	173	14	6	3	0.513 (0.282-0.933)	0.028
<i>CDH1</i>						
unmethylated (252)	210	28	11	3	reference	-
methylated (149)	130	14	5	0	0.856 (0.466-1.57)	0.62

by logistic regression analysis after adjustment for age, gender and *H. pylori* infection status.  
 ( ): number of subjects.

a decreased risk for the development of *DAPK* methylation (OR, 0.513; 95%CI, 0.282-0.933;  $p = 0.028$ ), and had no significant risk for the development of *CDH1* methylation ( $p = 0.62$ , Table 4).

Because mean age of our subjects was approximately 60 years old and gene methylation is increased with aging, we made further assessment in the subjects older than 60 years old. Then, -197 A carrier had an increased risk for the development of CIHM (OR, 1.80; 95%CI, 1.01-3.19;  $p = 0.046$ ), conversely \*1249 T carrier had a decreased risk (OR, 0.463; 95%CI, 0.224-0.959;  $p = 0.038$ , Table 5). When assessing the risk for each *DAPK* and

*CDH1* methylation, -197 A carrier tended to have an increased risk for the development of *CDH1* methylation ( $p = 0.068$ ), whereas \*1249 T carrier had a decreased risk for the development of *DAPK* methylation (OR, 0.427; 95%CI, 0.204-0.893;  $p = 0.024$ ).

When assessing the risk of HR (-197 A carrier with \*1249 CC genotype), HR tended to have an increased risk for CIHM ( $p = 0.081$ ), and had a significantly increased risk for the development of *DAPK* methylation (OR, 1.57; 95%CI, 1.04-2.35;  $p = 0.031$ , Table 6). In the subjects older than 60 years old, HR had an increased risk for CIHM (OR, 1.93; 95%CI, 1.10-3.39;

**Table 5 Risk of IL17A polymorphisms for gene methylation in the subjects older than 60 years old**

CIHM ( <i>DAPK</i> or <i>CDH1</i> )	CC	CT	TT	unknown	T carrier vs. CC; OR (95%CI)	p value
<i>IL17A</i> -197 G > A						
unmethylated (83)	GG	GA	AA	unknown	A carrier vs. GG; OR (95%CI)	p value
methylated (143)	38	39	6	0	reference	-
	46	79	18	0	1.80 (1.01-3.19)	0.046
<i>IL17A</i> *1249 C > T						
unmethylated (83)	CC	CT	TT	unknown	T carrier vs. CC; OR (95%CI)	p value
methylated (143)	63	15	5	0	reference	-
	124	13	5	1	0.463 (0.224-0.959)	0.038
<i>DAPK</i>						
<i>IL17A</i> -197 G > A						
unmethylated (103)	GG	GA	AA	unknown	A carrier vs. GG; OR (95%CI)	p value
methylated (123)	44	50	9	0	reference	-
	40	68	15	0	1.57 (0.897-2.75)	0.11
<i>IL17A</i> *1249 C > T						
unmethylated (103)	CC	CT	TT	unknown	T carrier vs. CC; OR (95%CI)	p value
methylated (123)	79	19	5	0	reference	-
	108	9	5	1	0.427 (0.204-0.893)	0.024
<i>CDH1</i>						
<i>IL17A</i> -197 G > A						
unmethylated (145)	GG	GA	AA	unknown	A carrier vs. GG; OR (95%CI)	p value
methylated (81)	60	71	14	0	reference	-
	24	47	10	0	1.76 (0.958-3.22)	0.068
<i>IL17A</i> *1249 C > T						
unmethylated (145)	CC	CT	TT	unknown	T carrier vs. CC; OR (95%CI)	p value
methylated (81)	116	22	6	1	reference	-
	71	6	4	0	0.590 (0.263-1.32)	0.20

by logistic regression analysis after adjustment for age, gender and *H. pylori* infection status.  
 ( ): number of subjects.

**Table 6 Risk of rs2275913 and rs3748067 for gene methylations**

<b>CIHM (DAPK or CDH1)</b>					
	HR	LR	unknown	HR vs. LR; OR (95%CI)	p value
over all					
unmethylated (153)	76	77	0	reference	-
methylated (248)	144	101	3	1.45 (0.955-2.20)	0.081
60 = <					
unmethylated (83)	38	45	0	reference	-
methylated (143)	89	54	0	1.93 (1.10-3.39)	0.023
<i>DAPK</i>					
over all					
unmethylated (205)	102	102	1	reference	-
methylated (196)	118	76	2	1.57 (1.04-2.35)	0.031
60 = <					
unmethylated (103)	49	54	0	reference	-
methylated (123)	78	45	0	1.91 (1.10-3.30)	0.021
<i>CDH1</i>					
over all					
unmethylated (252)	134	116	2	reference	-
methylated (149)	86	62	1	1.20 (0.787-1.83)	0.40
60 = <					
unmethylated (145)	73	72	0	reference	-
methylated (81)	54	27	0	2.01 (1.12-3.62)	0.020
<i>DAPK and CDH1</i>					
over all					
unmethylated (304)	160	141	3	reference	-
methylated (97)	60	37	0	1.44 (0.890-2.34)	0.14
60 = <					
unmethylated (165)	84	81	0	reference	-
methylated (61)	43	18	0	2.42 (1.25-4.68)	0.0087

HR: -197 A carrier with \*1249 CC genotype, LR: the others by logistic regression analysis after adjustment for age, gender and *H. pylori* infection status.  
 ( ): number of subjects.

$p=0.023$ ), and had an increased risk for the development of each *DAPK* methylation and *CDH1* methylation (OR, 1.91; 95%CI, 1.10-3.30;  $p=0.021$  and OR, 2.01; 95%CI, 1.12-3.62;  $p=0.020$ , respectively). In addition, HR had a more increased risk for the development of the methylation of both two genes (OR, 2.42; 95%CI, 1.25-4.68;  $p=0.0087$ ,  $1-\beta$ power = 0.709).

#### Association between IL17A polymorphisms and histological or serological gastric mucosal atrophy


Both atrophy and metaplasia scores were strongly correlated to the age in -197 A carrier ( $p=0.0012$  and  $0.0097$  by ANOVA, respectively, Figure 1), whereas there was no correlation between age and both scores in GG homozygote ( $p=0.092$  and  $p=0.73$ , respectively). Both scores were also strongly correlated to the age in \*1249

CC homozygote ( $p=0.0022$  and  $0.0064$ , respectively, Figure 2), whereas only atrophy score was weakly correlated to the age in T carrier ( $p=0.044$ ).


PG I/II ratio was significantly lower in *H. pylori* positive subjects than negative subjects in both -197 A carrier and GG homozygote, but in the former more strongly significant ( $p=0.0017$  and  $0.018$ , respectively, Figure 3). The association between \*1249 C > T and PG I/II ratio could not be evaluated, because the number of T carrier assessed was very small.

#### Discussion


Previously, we found no association between *IL17A* -197 G > A and methylation of both *DAPK* and *CDH1* [37]. In the present study with a large number of subjects, we confirm these results. However, our present



**Figure 1** Association between gastric mucosal atrophy and IL17A -197 G > A polymorphism. Both atrophy and metaplasia scores were significantly correlated to the age in A carrier (mutant carrier), whereas not in GG homozygote (wild homozygote).



**Figure 2** Association between gastric mucosal atrophy and IL17A \*1249 C > T polymorphism. Both atrophy and metaplasia scores were significantly correlated to the age in CC homozygote (wild homozygote), whereas only atrophy score was correlated to the age, but weakly, in T carrier (mutant carrier).



study showed that *IL17A* -197 A carrier tended to have an increased risk for the development of methylation, especially of *CDHI*, in the subjects older than 60 years old. In addition, the association of \*1249 C > T located in 3'-UTR was also investigated in the present study. The \*1249 T carrier was an increased risk factor for *DAPK* methylation and more strongly associated with the increased risk for gene methylation in comparatively older subjects (60 years = <). Over all, \*1249 C > T seemed to be more closely associated with gene methylation than -197 G > A. When assessing the association of *IL17A* haplotype, -197 mutant (A allele) carrier with \*1249 wild homo alleles (CC homozygote) had a more strongly increased risk for the development of gene methylation. Because allele frequency was less than prior assumptions, study population has been rather small. Therefore, the effect of type II error cannot be excluded in the assessment of allelic or genotype association of polymorphisms with gene methylation. This is one of the major limitations in our study.

Although the mechanisms of gene methylation are unknown, several factors may contribute to this methylation, such as exogenous carcinogens, generated reactive oxygen and host genetic differences [38]. One of the most important factors causing gene methylation in stomach is *H. pylori* infection [17], which first induces chronic superficial gastritis, which can progress to chronic atrophic gastritis, intestinal metaplasia, and dysplasia that leads toward gastric carcinoma [39]. In facts, the methylation of certain genes in non-neoplastic gastric mucosa correlate with *H. pylori* related histological or serological severity of gastritis [26] and gastric cancer occurrence [23,40,41]. IL-17A promotes the gastric mucosal inflammation via increased IL-8

production [8-10]. In addition, IL-17A induces increased levels of reactive oxygen species, which is one of the major inflammatory mediators [42]. Methylation of cytosine residues in DNA can be greatly influenced by hydroxyl free radical adducts on adjacent guanine residues [43]. IL-17A may contribute to increased gene methylation in *H. pylori*-induced gastric inflamed mucosa through these mechanisms.

Recently, it has been also reported that *IL17A* -197 AA homozygote is associated with several asthma-related traits and confers genetic susceptibility to childhood asthma in Chinese [31]. Furthermore, in our present study, both atrophy and metaplasia scores increased with age in -197 A carrier, whereas did not in GG homozygote. PG I/II ratio was more significantly decreased by *H. pylori* infection in A carrier than GG homozygote. In general, gastric mucosal atrophy develops as a result of severe inflammation that continued for a long term [39]. These suggest that *IL17A* -197 A allele may promote the inflammation. However, we found no significant difference of inflammation score among genotypes (data not shown). The degree of inflammation seems to fluctuate according to the inflammatory environment and is decreased with the progression of gastric mucosal atrophy. Therefore, it may be difficult to determine the degree of inflammation at one point. On the other hand, there is the possibility that *IL17A* polymorphisms may be associated with gastric mucosal atrophy by the mechanism other than promoting the inflammation. It is interesting to understand the effect of -197 A allele on the expression of IL-17A. Chen et al. demonstrated that *IL17A* -197 G > A was not related to PHA induced IL-17 production in PBMCs [31]. However, many kinds and subtypes of cells existed in PBMCs and



the networks of regulating immune response and cytokine production were complicated. In addition, IL-17A seemed to have dual actions, inflammatory or protective, depending of the co-expression of other cytokines [44]. Therefore, the function of *IL17A* -197 G > A in the inflammation is still well unknown.

On the other hand, to our best knowledge, there have been no reports of the association between *IL17A* \*1249 C > T, located in 3'-UTR, and human disorders. In general, microRNAs post-transcriptionally regulate the expression of mRNA through the binding to 3'-UTR of target genes. Therefore, altered conformation of 3'-UTR may affect the binding of microRNAs to mRNA. In our present study, \*1249 mutant carrier had a decreased risk for gene methylation, especially *DAPK*, in comparative older subjects. Moreover, it seemed that the repressor activity of \*1249 T allele took part in the inflammations more strongly than the stimulatory effects of -197 A allele. In addition, both atrophy and metaplasia scores increased with age in \*1249 wild homozygote (CC genotype), whereas only atrophy score weakly correlated to the age in mutant carrier. These suggest that \*1249 T allele may protect the inflammation. That is, we speculate that *IL17A* -197 mutant allele may promote and \*1249 mutant allele may protect the inflammation.

Based on these results, we evaluated the association of HR, as an inflammation promoting haplotype, (-197 mutant carrier with \*1249 wild homozygote) with gene methylation. In the subjects older than 60 years old, HR was more strongly associated with the increased risk for both *DAPK* and *CDHI* methylation, although overall with only *DAPK* methylation. This suggests that both -197 G > A and \*1249 C > T may affect on the expression or function of IL-17A coordinately. The reason why significant differences were observed in comparatively older subjects may be because gene methylation is age-related change and/or because methylation depends on severity and periods of chronic inflammation. We speculate that this difference becomes clear after gene methylation progressed at the old age.

## Conclusions

In conclusions, the inflammation promoting allele of *IL17A* -197 G > A (rs2275913) and \*1249 C > T (rs3748067) was significantly associated with the increased risk for the development of gene methylations in non-cancerous gastric mucosa. That is, in -197 A allele carrier with \*1249 CC homozygote, the methylation of *DAPK* and *CDHI* is increased gradually, but more rapidly, with age and altered gastric mucosal structure induced by *H. pylori* infection than in the others.

## Abbreviations

ANOVA: Analysis of variance; *CDHI*: E-cadherin gene; *CDKN2A*: Cyclin-dependent kinase inhibitor 2A gene; CI: Confidence interval; CIHM: CpG

island high methylated; *DAPK*: Death-associated protein kinase gene; *H. pylori*: *Helicobacter pylori*; IL: Interleukin; *IL17A*: Interleukin 17A gene; MSP: Methylation-specific PCR; OR: Odds ratio; PBMC: Peripheral blood mononuclear cell; PG: Pepsinogen; PHA: Phytohemagglutinin; SSCP: Single Strand Conformation Polymorphism; SD: Standard deviation; UTR: Untranslated region.

## Competing interests

The author(s) declare that they have no competing interests.

## Authors' contributions

TA analyzed the data, wrote the paper and was responsible for the conception of the study and designed the study. TT participated in the design of the study. MT and TS obtained the samples and the data. All authors approved of the final manuscript prior to submission.

## Acknowledgement

This work was partially supported by Grant for Specially Promoted Research from Kanazawa Medical University (SR2012-01).

## Author details

<sup>1</sup>Department of Gastroenterology, Kanazawa Medical University, 1-1, Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan. <sup>2</sup>Department of Gastroenterology, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Japan.

Received: 15 January 2012 Accepted: 9 July 2012

Published: 24 July 2012

## References

1. Rutitzky LI, da Rosa JR L, Stadecker MJ: Severe CD4 T cell-mediated immunopathology in murine schistosomiasis is dependent on IL-12p40 and correlates with high levels of IL-17. *J Immunol* 2005, **175**:3920-3926.
2. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. *J Biol Chem* 2003, **278**:1910-1914.
3. Kolls JK, Linden A: Interleukin-17 family members and inflammation. *Immunity* 2004, **21**:467-476.
4. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S: Interleukin-17. *Int Rev Immunol* 1998, **16**:541-551.
5. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP: IL-17 stimulates the production and expression of proinflammatory and hematopoietic cytokines, IL-1b and TNF-a, by human macrophages. *J Immunol* 1998, **160**:3513-3521.
6. Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, Skoogh BE, Linden A: Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. *J Immunol* 1999, **162**:2347-2352.
7. Lizza F, Parrello T, Monteleone G, Sebkova L, Romano M, Zarrilli R, Imeneo M, Pallone F: Up-Regulation of IL-17 Is Associated with Bioactive IL-8 Expression in *Helicobacter pylori*-Infected Human Gastric Mucosa. *J Immunol* 2000, **165**:5332-5337.
8. Sebkova L, Pellicano A, Monteleone G, Grazioli B, Guarneri G, Imeneo M, Pallone F, Lizza F: Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in *Helicobacter pylori*-infected human gastric epithelial cells. *Infect Immun* 2004, **72**:5019-5026.
9. Mizuno T, Ando T, Nobata K, Tsuzuki T, Maeda O, Watanabe O, Minami M, Ina K, Kusugami K, Peek RM, Goto H: Interleukin-17 levels in *Helicobacter pylori*-infected gastric mucosa and pathologic sequelae of colonization. *World J Gastroenterol* 2005, **11**:6305-6311.
10. Shiomi S, Toriie A, Imamura S, Konishi H, Mitsufoji S, Iwakura Y, Yamaoka Y, Ota H, Yamamoto T, Imanishi J, Kita M: IL-17 is involved in *Helicobacter pylori*-Induced Gastric Inflammatory Responses in a Mouse Model. *Helicobacter* 2008, **13**:518-524.
11. Parkin DM, Bray F, Ferlay J, Pisani P: (2005) Global cancer statistics, 2002. *CA Cancer J Clin* 2005, **55**:74-108.
12. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006, **24**:2137-2150.

13. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelmann JH, Orentreich N, Sibley RK: **Helicobacter pylori** infection and the risk of gastric carcinoma. *N Engl J Med* 1991, **325**:1127–1131.
14. Blaser MJ, Parsonnet J: Parasitism by the 'slow' bacterium *Helicobacter pylori* leads to altered gastric homeostasis and neoplasia. *J Clin Invest* 1994, **94**:4–8.
15. Huang JQ, Sridhar S, Chen Y, Hunt RH: **Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer.** *Gastroenterology* 1998, **114**:1169–1179.
16. Esteller M, Corn PG, Baylin SB, Herman JG: **A gene hypermethylation profile of human cancer.** *Cancer Res* 2001, **61**:3225–3229.
17. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Yonemura J, Maeda Y, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nakagawa Y, Nagasaka M, Iwata M, Hirata I, Arisawa T: **Increased Number of CpG Island Hypermethylation in Tumor Suppressor Genes of Non-Neoplastic Gastric Mucosa Correlates with Higher Risk of Gastric Cancer.** *Digestion* 2010, **82**:27–36.
18. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB: **Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon.** *Nat Genet* 1994, **4**:536–540.
19. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP: **Aging and DNA methylation in colorectal mucosa and cancer.** *Cancer Res* 1998, **23**:5489–5494.
20. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA: **Accelerated age-related CpG island methylation in ulcerative colitis.** *Cancer Res* 2001, **61**:3573–3577.
21. Bian YS, Osterheld MC, Fontollet C, Bosman FT, Benhattar J: **p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.** *Gastroenterology* 2001, **122**:1113–1121.
22. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T: **High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk.** *Clin Cancer Res* 2006, **12**:989–995.
23. Tahara T, Arisawa T, Sibata T, Wang FY, Nakamura M, Sakata M, Nagasaka M, Takagi T, Kamiya Y, Fujita H, Nakamura M, Hasegawa S, Iwata M, Takahama K, Watanabe M, Hirata I, Nakano H: **Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium.** *Digestion* 2007, **75**:54–61.
24. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS: **Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation.** *Am J Pathol* 2003, **163**:1551–1556.
25. Kang GH, Lee S, Lim JS, Jung HY: **Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis.** *Lab Invest* 2003, **83**:635–641.
26. Tahara T, Arisawa T, Shibata T, Nakamura M, Yoshioka D, Okubo M, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nakagawa Y, Nagasaka M, Iwata M, Takahama K, Watanabe M, Yamashita H, Hirata I: **Increased number of methylated CpG islands correlates with Helicobacter pylori infection, histological and serological severity of chronic gastritis.** *Eur J Gastroenterol Hepatol* 2009, **21**:613–619.
27. Shibata T, Tahara T, Hirata I, Arisawa T: **Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis.** *Hum Immunol* 2009, **70**:547–551.
28. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Nakamura M, Yoshioka D, Arima Y, Okubo M, Hirata I, Nakano H: **The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis.** *J Clin Immunol* 2008, **28**:44–49.
29. Nordang GBN, Viken MK, Hollis-Moffatt JE, Merriman TR, Forre OT, Helgetveit K, Kvien TK, Lie BA: **Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand.** *Rheumatology* 2009, **48**:367–370.
30. Wu X, Zeng Z, Chen B, Yu J, Xue L, Hao Y, Chen M, Sung JJ, Hu P: **Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer.** *Int J Cancer* 2010, **127**:86–92.
31. Chen J, Deng Y, Zhao J, Luo Z, Peng W, Yang J, Ren L, Wang L, Fu Z, Yang X, Liu E: **The polymorphism of IL-17 G-152A was associated with childhood asthma and bacterial colonization of the hypopharynx in bronchiolitis.** *J Clin Immunol* 2010, **30**:539–545.
32. Katzenellenbogen RA, Baylin SB, Herman JG: **Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies.** *Blood* 1999, **93**:4347–4353.
33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: **Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.** *Proc Natl Acad Sci USA* 1996, **93**:9821–9826.
34. Dixon MF, Genta RM, Yardley JH, Correa P: **Classification and grading of gastritis: the updated Sydney system.** *Am J Surg Pathol* 1996, **20**:1161–1181.
35. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG: **CpG island methylation in premalignant stages of gastric carcinoma.** *Cancer Res* 2001, **61**:2847–2851.
36. Pestov DG, Strezoska Z, Lau LF: **Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition.** *Mol Cell Biol* 2001, **21**:4246–4255.
37. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Yonemura J, Maeda Y, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nakagawa Y, Nagasaka M, Iwata M, Hirata I, Arisawa T: **Effect of polymorphisms of IL-17A, -17F and MIF genes on CpG island hyper-methylation (CIHM) in the human gastric mucosa.** *Int J Mol Med* 2009, **24**:563–569.
38. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nakagawa Y, Nagasaka M, Iwata M, Takahama K, Watanabe M, Hirata I, Arisawa T: **MTHFR 677T carrier influences the methylation status of H. Pylori-infected gastric mucosa in older subject.** *Dig Dis Sci* 2009, **54**:2391–2398.
39. Correa P: **Human gastric carcinogenesis: a multistep and multifactorial process.** *First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention.* *Cancer Res* 1992, **52**:6735–6740.
40. Kaise M, Yamasaki T, Yonezawa J, Miwa J, Ohta Y, Tajiri H: **CpG island hypermethylation of tumor-suppressor genes in H. pylori - infected non-neoplastic gastric mucosa is linked with gastric cancer risk.** *Helicobacter* 2008, **13**:35–41.
41. Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, Ichinose M, Sugimura T, Ushijima T, Saito D: **Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers.** *Cancer Epidemiol Biomarkers Prev* 2006, **15**:2317–2321.
42. Pietrowski E, Bender B, Huppert J, White R, Luhmann HJ, Kuhlmann CRW: **Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H oxidase derived reactive oxygen species.** *J Vasc Res* 2011, **48**:52–58.
43. Weitzman SA, Turk PW, Milkowski D, Kozlowski K: **Free radical adducts induce alterations in DNA cytosine methylation.** *Proc Natl Acad Sci USA* 1994, **91**:1261–1264.
44. Ouyang W, Kolls JK, Zheng Y: **The biological functions of T helper 17 cell effector cytokines in inflammation.** *Immunity* 2008, **28**:454–467.

doi:10.1186/1471-2350-13-59

**Cite this article as:** Arisawa et al.: Influence of IL17A polymorphisms on the aberrant methylation of DAPK and CDH1 in non-cancerous gastric mucosa. *BMC Medical Genetics* 2012 **13**:59.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at  
www.biomedcentral.com/submit

